Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers
Clinical trial NCT02222428 · COMPLETED
Trial details
- NCT number
- NCT02222428
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-04-01
- Primary completion
- 2009-07-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.